|
gptkbp:instanceOf
|
antiretroviral therapy
non-nucleoside reverse transcriptase inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
1996
|
|
gptkbp:ATCCode
|
J05AG01
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
|
|
gptkbp:brand
|
gptkb:Viramune
|
|
gptkbp:CASNumber
|
129618-40-2
|
|
gptkbp:category
|
antiviral drug
HIV/AIDS drug
|
|
gptkbp:contraindication
|
hypersensitivity
severe liver impairment
|
|
gptkbp:discoveredBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:drugInteraction
|
gptkb:rifampicin
gptkb:ketoconazole
oral contraceptives
|
|
gptkbp:eliminationHalfLife
|
25-30 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C15H14N4O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nevirapine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 reverse transcriptase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
60%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fever
nausea
rash
hepatotoxicity
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:NNRTIs
|
|
gptkbp:bfsLayer
|
5
|